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The demographics of squamous cell carcinoma of the head and neck (SCCHN) is marked 
by a growing number of patients aged 65 and over, which is in line with global projections 
for other cancer types. In developed countries, more than half of new SCCHN cases are 
diagnosed in older people, and in 15 years from now, the proportion is expected to rise 
by more than 10%. Still, a high-level evidence-based consensus to guide the clinical 
decision process is strikingly lacking. The available data from retrospective studies and 
subset analyses of prospective trials suffer from a considerable underrepresentation 
of senior participants. The situation is even more challenging in the recurrent and/or 
metastatic setting, where usually only palliative measures are employed. Nevertheless, 
it is becoming clear that, if treated irrespective of chronological age, fit elderly patients 
in a good general condition and with a low burden of comorbidities may derive a similar 
survival advantage as their younger counterparts. Despite that, undertreatment rep-
resents a widespread phenomenon and, together with competing non-cancer mortality, 
is suggested to be an important cause of the worse treatment outcomes observed in this 
population. Due to physiological changes in drug metabolism occurring with advancing 
age, the major concerns relate to chemotherapy administration. In locally advanced 
SCCHN, concurrent chemoradiotherapy in patients over 70  years remains a point of 
controversy owing to its possibly higher toxicity and questionable benefit. However, 
accumulating evidence suggests that it should, indeed, be considered in selected cases 
when biological age is taken into account. Results from a randomized trial conducted 
in lung cancer showed that treatment selection based on a comprehensive geriatric 
assessment (CGA) significantly reduced toxicity. However, a CGA is time-consuming 
and not necessary for all patients. To overcome this hurdle, geriatric screening tools 
have been introduced to decide who needs such a full evaluation. Among the various 
screening instruments, G8 and Flemish version of the Triage Risk Screening Tool were 
prospectively verified and found to have prognostic value. We, therefore, conclude that 
also in SCCHN, the application of elderly specific prospective trials and integration of 
clinical practice-oriented assessment tools and predictive models should be promoted.
Keywords: head and neck cancer, comprehensive geriatric assessment, screening tools, surgery, radiotherapy, 
chemotherapy, targeted therapy, immunotherapy
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iNTRODUCTiON
Head and neck cancer refers to a heterogeneous group of malig-
nancies originating from the upper aero-digestive tract, includ-
ing the oral cavity and lip, the pharynx, the larynx, the salivary 
glands, the ear, the nasal cavity, and the paranasal sinuses (1, 2). 
More than 90% of the head and neck cancers are of squamous 
cell origin and are classified as squamous cell carcinomas of 
the head and neck (SCCHNs). In 2012, it was estimated that 
SCCHN of the lip, oral cavity, pharynx, and larynx accounted for 
a total of 686,300 new cases and 375,700 cancer deaths world-
wide, thus representing the seventh most common neoplasm in 
terms of incidence and mortality (3). Forty percent of patients 
present with early disease (stages I and II). In this setting, cure 
rates around 80% have been achieved with single-modality 
treatments, either surgery or radiotherapy. The remaining 60% 
of cases are diagnosed with advanced stages encompassing 
locally advanced (stages III and IVA/B) and metastatic tumors 
(stage IVC). Despite a multimodality approach, the majority 
of patients with locally advanced SCCHN develop recurrences 
or distant metastases, so that 5-year overall survival does not 
usually exceed 60% (4). The presence of distant metastases or 
recurrent disease unsuitable for surgery or radiotherapy por-
tends a poor prognosis with an expected survival in the order 
of 6–10 months (5).
In 1971, Abdel Omran coined the term “epidemiological 
transition” to explain the changes in population with respect 
to mortality and disease patterns. According to this theory, all 
societies experience a shift from infectious (cholera and tubercu-
losis) to chronic and degenerative diseases (cardiovascular and 
neoplastic), which is paralleled by increasing life expectancy (6). 
Analogously, “cancer transition” refers to a shift from infection-
related cancers to cases associated with reproductive, dietary, 
and hormonal factors (7). The first concept reflects the evolving 
demographic landscape of head and neck cancer, since the global 
cancer burden, including SCCHN, is rising with the predilection 
of the elderly population. However, the second point concern-
ing the “cancer transition” should be interpreted with caution. 
Although the major risk factors for head and neck carcinogen-
esis pertain to behavioral patterns [i.e., tobacco abuse, alcohol 
consumption, and human papillomavirus (HPV) infection] and 
are, therefore, preventable, they still pose a serious challenge for 
public health policy (8). In this regard, driven by the tobacco 
epidemics, oral cancer incidence rates declined among men and 
women in countries with effective prevention strategies dur-
ing 1983–2002, while they increased elsewhere. In contrast, a 
growing incidence of oropharyngeal cancer has been observed 
predominantly in economically developed countries during the 
same period, owing most probably to the increased exposure to 
HPV infection (9, 10).
In this review article, we address issues related to the man-
agement of elderly patients with SCCHN. Notwithstanding 
the growing participation of older patients in cancer care, this 
population has been chronically underrepresented in clinical 
trials mainly due to disqualifying medical conditions. This 
remains to be a continuing problem despite the fact that their 
willingness to participate in clinical trials does not seem to pose a 
barrier (11). At present, only 3.4% of studies worldwide are ongo-
ing in patients over 65 years (12). The resulting lack of evidence-
based data hampers effective implementation of novel drugs and 
development of clinical practice guidelines in the older patient 
population. Herein, we specifically focus on various aspects of 
geriatric assessment in oncology and discuss available treatment 
modalities for patients with primary non-metastatic SCCHN as 
well as those with recurrent and/or metastatic (R/M) disease.
AGe, AGiNG, AND THe AGe OF BOOMeRS
As documented in many epidemiological studies, there is a 
marked association between tumor development and aging. 
Advanced age is the major risk factor for cancer, which, in turn, 
represents the second most common cause of death for persons 
over 65 years in Europe (13, 14). In accordance with demographic 
projections showing the steadily growing number of the elderly 
people, the global cancer burden will nearly double in the near 
future with a preferential increase in the developing world. By 
2030, up to 22 million new cases (12 million in those 65 years or 
older) and 13 million cancer deaths (8.4 million in those 65 years 
or older) are to be expected worldwide each year, excluding non-
melanoma skin cancers, which are frequent and generally well 
curable (15). Interestingly, cancer incidence and mortality have 
been reported to decrease or plateau in the oldest population 
(over 90 years) owing partly to the selection of less vulnerable 
individuals (16).
Squamous cell carcinoma of the head and neck follows the same 
epidemiologic trends. According to the 2010 cancer incidence 
projections for the United States, 54% of malignant head and neck 
cancer cases occurred in patients older than 65 years of age. By 
2030, the proportion is expected to rise to 66% (17). Currently, 
for oral cavity and pharynx cancers, the median age at diagnosis 
is 62 years, whereas it is 65 years in case of larynx carcinoma (4). 
Although the major risk factors for SCCHN in the elderly are 
still tobacco and alcohol consumption, their prevalence is lower 
than in an unselected population (40 versus 70%), underscoring 
age alone as an important risk factor. Compared to younger 
patients, older age groups have a higher ratio of female cases and 
are more likely to have primary tumors located in the oral cavity 
and larynx, but less in the hypopharynx. Metastatic spread to the 
regional lymph nodes and HPV-associated oropharyngeal cancer 
also appear to be less frequent in the elderly (18).
But how to define old age? This is one of the key questions; 
unfortunately, no universally accepted criteria that would 
facilitate clinical decision-making exist. The elderly are usually 
classified into young-old (65–75  years), old-old (76–85  years), 
and oldest-old groups (>85  years) (19). This categorization 
has been adopted by the National Institute on Aging and the 
National Institutes of Health, whereas most clinical studies use 
the age of 70 years (or even 75) as a cut-off defining the elderly 
(20). However, chronological age is not a reliable predictor of life 
expectancy, functional reserve, or the risk of treatment side effects. 
Aging is associated with a progressive loss of functional reserve of 
multiple organ systems, increased prevalence of chronic diseases, 
and enhanced susceptibility to stress. These age-related changes 
occur at different rates in different individuals. Moreover, they 
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are usually accompanied by fluctuations in social support and 
economic resources. Hence, chronological age provides limited 
information for individual patient management since it does not 
always correlate with biological parameters (19, 21).
In 2011, the first wave of the Baby Boom generation, born after 
the Second World War between 1946 and 1964, reached retire-
ment age. Unlike their parents’ generation, the elderly Boomers 
are different. They demand more involvement and competence in 
their health care, pursue social engagement and healthy lifestyle, 
continue to have physical and intellectual activity, and use the 
Internet and modern information technologies (22). Thus, it is to 
expect that in this patient population, the gap between chrono-
logical and biological age will continue to grow together with an 
increasing need for strengthening the geriatric competence of 
clinicians in routine practice.
HOw TO APPROACH AN eLDeRLY 
PATieNT wiTH HeAD AND NeCK CANCeR
At first glance, results from clinical trials could be interpreted as 
ambiguous. On the one hand, geriatric SCCHN patients expe-
rienced similar outcomes when treated similarly as the younger 
cohort, but on the other hand, worse survival was noted due 
to higher comorbidity status and competing causes of mortal-
ity (23,  24). To resolve this discrepancy, we have to take into 
account the heterogeneity of the elderly population represented 
by functional and not chronologic age. In this respect, several 
studies have demonstrated that radical surgical interventions and 
radiotherapy with curative intent can be delivered safely to older 
adults without significant comorbid conditions. Such patients 
can employ effective coping strategies and maintain quality of life 
comparable with their younger counterparts (23, 25, 26). Despite 
these arguments, many physicians concerned about excessive 
toxicity still tend to use chronological age a sole discriminator 
and opt for non-standard or less aggressive therapies in otherwise 
fit elderly persons (23).
With the aim of assessing the extent of undertreatment, a large 
retrospective analysis of 14,909 oropharyngeal cancer cases cat-
egorized data from Surveillance, Epidemiology, and End Results 
(SEER) program by treatment (surgery, radiation, combined, 
or none) and age (45–54, 55–64, 65–74, 75–84, >85 years). The 
following three conclusions were made. First, after the age of 
55, the proportion of those who did not receive any of the treat-
ment modalities significantly increased, whereas the number 
of patients treated with a combined approach (surgery plus 
radiation) significantly decreased. Second, Kaplan–Meier curves 
for disease-specific survival revealed that age groups 65–74 and 
75–84 years substantially benefited from surgery, radiotherapy, or 
a combined modality. Finally, the relative risk reduction of death 
from oropharyngeal cancer conferred by combined therapy was 
similar across all age categories from 45 to 84 years (27).
In line with these findings are retrospective data reported by 
others, indicating that only half of the older patients are managed 
according to institutional policies (28). The resulting suboptimal 
treatment has been hypothesized as one of the reasons for shorter 
survival. In oral cavity and pharynx cancers, the SEER database 
from 2006 to 2012 revealed 5-year overall survival of 69 and 56% 
for patients younger and older than 65  years, respectively (4). 
Other factors that may have contributed to such difference in out-
comes include serious age-related comorbidities and individual 
decisions to avoid receiving full-dose regimens (29). This is in 
accordance with the results of a long-term prospective observa-
tional study of 266 subjects showing that chronological age has no 
independent prognostic value as opposed to comorbidities and 
non-standard treatment (30).
One possible solution of how to address the complexity in 
delivering patient care at an individual level is a team approach 
in treatment planning represented by multidisciplinary tumor 
boards. These meetings should offer a collaborative review of 
each case with a special attention to disease factors (site, stage, 
biology, risk factors for locoregional, or distant relapse), patient 
characteristics (age, sex, performance and nutritional status, 
comorbid conditions, oral health, lifestyle habits, socio-economic 
background), treatment options, and patient preferences. A geri-
atrician is not always available, and practicing oncologists should, 
therefore, familiarize themselves with some of the assessment 
tools described below.
GeRiATRiC evALUATiON iN ONCOLOGY
The complexity of geriatric care depends on several characteristics, 
including functional status, comorbidities, cognition, nutritional 
status, social support, and psychological state (depression) (31). 
They all have been linked to survival, and their deterioration with 
advancing age is more or less caused by progressively declining 
organ functions and associated metabolic changes. In an outpa-
tient oncology clinic setting, the following indispositions and 
their prevalence were reported in older cancer patients: comor-
bidity (>90%, severe in 30–40%), functional status dependence 
measured by instrumental activities of daily living (IADL, see 
below) (50–60%), nutritional compromise (30–50%), depression 
(20–40%), cognitive impairment (25–35%), functional status 
dependence measured by activities of daily living (ADL, see 
below) (about 20%), and Eastern Cooperative Oncology Group 
(ECOG) performance status score ≥2 (about 20%) (32).
Estimation of life expectancy is paramount in cancer coun-
seling. It allows us to tailor the decision-making process by 
assessing a risk–benefit ratio for planned interventions. About 
half of patients over 70 years of age can be treated with a standard 
oncologic approach, while the other half will require more exten-
sive care (33). Consequently, geriatric evaluation using different 
scales and tools has been used in clinical practice to optimize 
treatment delivery in this patient population.
Functional Status, Comorbidities, 
and Nutritional Status
Although often used as traditional oncologic measures, perfor-
mance status scores alone (e.g., Karnofsky or ECOG) do not 
convey sufficiently accurate information about functional status, 
comorbidities, and physiological reserves. However, these three 
characteristics are key components in differentiating between a 
fit and frail person of the same age. Functional status comprises 
TABLe 1 | Components of a comprehensive geriatric assessment with 
tools for their measurement, adapted from Ref. (18, 33, 39).
Assessment of functioning Social assessment
Definition: ability to live independently 
at home and in the community, physical 
performance (mobility, balance, fall risk)
Measurement: ADLs, IADLs, history of 
falls, timed up and go, short physical 
performance battery, handgrip testing
Definition: adequate social support 
to undergo treatment
Measurement: needs assessment 
of financial capabilities, 
transportation, and caregiver 
status; Medical Outcomes Survey 
Social Support
Medical assessment Psychological assessment
Comorbidity and medication
Measurement: Charlson Comorbidity 
Scale, Adult Comorbidity Evaluation 27, 
Cumulative Illness Rating Scale-
Geriatrics, comorbidity count and 
severity, medication count, Beers criteriaa
Nutritional status
Measurement: mini-nutritional 
assessment, weight loss, body mass 
index
Cognition
Measurement: Mini-Mental Status 
Examination, Blessed Orientation 
Memory Scale, Short Portable 
Mental Status Questionnaire, 
Montreal Cognitive Assessment
Depression and anxiety
Measurement: Geriatric Depression 
Scale, Hospital Anxiety and 
Depression Scale
aBeers criteria for potentially inappropriate medication use in older adults.
ADLs, activities of daily living; IADLs, instrumental activities of daily living.
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an assessment of the patient’s ability to complete ADLs, such as 
the ability to bathe, dress, feed oneself, maintain continence, and 
transfer from bed or chair without assistance, and IADLs, like 
doing housework, using transportation, shopping, and taking 
medications. Functional status assessed by IADL and also ECOG 
performance status predict postoperative morbidity, toxicity to 
chemotherapy, and survival (31). In a study of 203 elderly cancer 
patients, the association of ECOG performance status with ADL/
IADL was moderate, but it was low or absent when compared 
with comorbidity scales. Similarly, the correlation between ADL/
IADL and comorbidities was low or absent (34).
Comorbidities are defined as additional concurrent diseases 
unrelated to cancer. Due to worsening pulmonary functions 
with reduced vital capacities and gas exchange, weaker cardiac 
output, decreasing renal blood flow, and changes in hepatic 
metabolism, the prevalence of comorbid conditions increases 
with growing age (28). In addition, cumulative exposure to 
various risk factors and etiological agents is higher in older 
adults. Excessive use of tobacco and alcohol results in chronic 
obstructive pulmonary disease, susceptibility to recurrent 
infections, liver steatosis and cirrhosis, poor oral hygiene 
and dental condition, malnutrition, weight loss, frailty, low-
performance status, Wernicke’s encephalopathy, and other 
neurological disorders (35). About 60% of SCCHN patients 
suffer from at least one coexisting illness, and this percentage 
is estimated to approach 75% in a population over 70 years old 
(36, 37). Piccirillo et  al. reviewed medical records of 19,268 
patients with seven different tumor types from a hospital 
registry. Cox proportional hazard assessment corrected for 
age, race, sex, and cancer stage revealed that comorbidity 
measured by the Adult Comorbidity Evaluation 27 (ACE-27) is 
an independent prognostic factor. This was confirmed among 
1,086 subjects with head and neck cancer, where hazard ratios 
associated with mild, moderate, and severe comorbidities 
were 1.03 (0.80–1.32), 1.92 (1.50–2.47), and 2.48 (1.77–3.47), 
respectively (38). In a retrospective analysis of 103 patients 
with primary or recurrent SCCHN, this independent prog-
nostic value for survival was shown for both the ACE-27 and 
the Charlson Comorbidity Scale (39). More recently, a Dutch 
study showed that the inclusion of the comorbidity score 
measured by the ACE-27 led to a further refinement of the 
prognostic model (including HPV status, smoking status, and 
T and N stage) for oropharyngeal squamous cell cancer, as 
earlier described by Ang et al. (40, 41).
Nutritional deficiency is the third most commonly encoun-
tered factor in older cancer patients, where even small amounts 
of weight loss (less than 5% of body weight) can have clinical 
significance (31, 32). In SCCHN, the prevalence is probably even 
higher due to a reduced oral intake resulting from associated 
pain and difficulties with swallowing. Moreover, it may be further 
aggravated by local treatment such as surgery and radiotherapy. 
According to its severity, available interventions include dietetic 
counseling, oral nutritional supplements, or artificial nutrition 
usually by means of percutaneous endoscopic gastrostomy 
(PEG) (35). With respect to the latter, it needs to be mentioned 
that the role of prophylactic PEG tube placement still remains 
a point of controversy (42). A related issue relevant to SCCHN 
patients is the evaluation of the dental and periodontal health 
status as it is directly linked to good nutritional intake (35).
Comprehensive Geriatric Assessment
Comprehensive geriatric assessment (CGA) has been introduced 
by geriatricians to estimate overall health status of an individual, 
detect unknown deficits, predict survival, and anticipate on 
adverse effects of chemotherapy and postoperative complica-
tions. It includes validated tests for evaluation of functional 
status, comorbid conditions, cognition, nutritional status, social 
support, psychological state, and polypharmacy (18, 33, 39, 
43, 44) (Table 1). A CGA can predict morbidity and mortality not 
only in the general geriatric population but also in elderly patients 
with cancer, where it was shown to modify the initially proposed 
anticancer treatment in up to 49% of patients (31, 45, 46). This 
multidimensional interdisciplinary diagnostic process is, thus, 
both a diagnostic and therapeutic tool aiming at improving qual-
ity of life, compliance to therapy, and overall survival. For timely 
detection of deterioration, measurements can be repeated during 
follow-up. With a notable remark that results from randomized 
trials are available mostly for non-malignant diseases, a CGA 
has been recommended by the National Comprehensive Cancer 
Network (NCCN), the European Organisation for Research and 
Treatment of Cancer (EORTC), and the International Society of 
Geriatric Oncology (SIOG) (47–49).
The first randomized trial in cancer patients to prospectively 
evaluate CGA-directed treatment selection is the ESOGIA-
GFPC-GECP 08-02 study conducted in 494 elderly patients with 
advanced non-small-cell lung cancer. Participants aged 70 years 
and above were randomized between chemotherapy allocation 
based on performance status and treatment choice according 
to a CGA. In the former arm, the investigators defined a group 
of patients with performance status ≤1 and age ≤75  years, 
TABLe 2 | G8 screening questionnaire in elderly patients (43).
items Score
1. Has food intake declined over the 
past 3 months due to loss of appetite, 
digestive problems, chewing, or 
swallowing difficulties?
0 = severe reduction in food intake
1 = moderate reduction in food intake
2 = normal food intake
2. Weight loss during the last 3 months 0 = weight loss more than 3 kg
1 = does not know
2 = weight loss between 1 and 3 kg
3 = no weight loss
3. Mobility 0 = bed or chair bound
1 = able to get out of bed/chair but  
   does not go out
2 = goes out
4. Neuropsychological problems 0 = severe dementia or depression
1 = mild dementia or depression
2 = no psychological problems
5. Body mass index (BMI) = weight 
in kg/height in m2
0 = BMI <19
1 = 19 ≤ BMI < 21
2 = 21 ≤ BMI < 23
3 = BMI ≥ 23
6. Takes more than three medications 
per day?
0 = yes
1 = no
7. In comparison with other people of 
the same age, how does the patient 
consider his/her health status?
0.0 = not as good
0.5 = does not know
1.0 = as good
2.0 = better
8. Age 0 = over 85 years
1 = 80–85 years
2 = under 80 years
Total score 0–17 (abnormal if ≤14)
Reprinted with permission. © 2014 American Society of Clinical Oncology. All rights 
reserved.
TABLe 3 | Flemish version of the Triage Risk Screening Tool (43).
items Score
Yes No
1. Presence of cognitive impairment (disorientation,  
diagnosis of dementia, or delirium)
2 0
2. Lives alone or no caregiver available, willing, or able 1 0
3. Difficulty with walking or transfers or fall(s) in the past 
6 months
1 0
4. Hospitalized in the last 3 months 1 0
5. Polypharmacy: ≥5 medications 1 0
Total score 0–6
abnormal if ≥2 within the geriatric population and ≥1 within the oncologic 
population
Reprinted with permission. © 2014 American Society of Clinical Oncology. All rights 
reserved.
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who received combination chemotherapy, and a group of older 
patients and/or patients with worse performance status treated 
with single-agent regimen. The latter arm was stratified into 
fit, vulnerable, and frail categories that received combination 
chemotherapy, single-agent regimen, or supportive care only, 
respectively. There was no difference in the primary or second-
ary end points (treatment failure free survival, overall survival, 
progression-free survival, tolerability, quality of life). However, 
the CGA-guided approach significantly reduced all-grade 
toxicity and treatment failure as a result of toxicity (50, 51). In 
SCCHN, the first randomized controlled study using a CGA is the 
EGeSOR trial that is currently ongoing in France. Both control 
and experimental groups receive standard-of-care management, 
while, in the latter group, CGAs are performed by geriatricians at 
predefined time points. The primary endpoint is a composite of 
death, ADL, and weight loss ≥ 10%. The investigators expect at 
least a 10% decrease in the primary endpoint to be achieved by 
the intervention (29).
However, owing to the fact that a CGA is time-consuming, 
requires skilled professionals, and is not necessary for all patients, 
it is rarely performed in oncology practices. Consequently, a 
two-step approach has been developed furnishing clinicians with 
geriatric screening tools to decide: (i) what patient needs a full 
assessment, (ii) who will benefit from a specific examination, and 
(iii) in which cases no further testing is required.
Geriatric Screening Tools
Several geriatric screening tests have been used in oncol-
ogy including the G8, the Flemish version of the Triage Risk 
Screening Tool (fTRST), the Groningen Frailty Indicator, the 
Vulnerable Elders Survey-13 (VES-13), and an abbreviated 
CGA. The G8 and the fTRST have been prospectively validated 
in a non-interventional, multicentre study (Tables  2 and 3). 
Both instruments demonstrated high sensitivity and moderate 
negative predictive value to identify patients with a geriatric 
risk profile. Moreover, they were prognostic for overall survival, 
especially the G8 (43). In a recent update of SIOG recommenda-
tions, a systematic review of 44 studies on the use of 17 different 
screening tools was reported. The G8 proved to be more or 
equally sensitive than other tests. The authors concluded that the 
screening tools should not replace a full assessment. However, 
a busy practice setting entitles the physicians to use them for 
triage decisions prior to a CGA (52).
Stratifying elderly head and neck cancer patients according 
to the VES-13 test into frail, vulnerable, and fit cohorts, Perri 
et al. proposed possible approaches for their management. Frail 
(VES-13 score = 3) and vulnerable (score = 1–2) groups should 
undergo a CGA, while standard therapy is advised for the rest. 
Importantly, physicians should respect physiological changes in 
the elderly concerning drug metabolism as well as limited bone 
marrow reserve, the latter being reflected in guidelines for growth 
factor prophylaxis. Where indicated, a CGA tailors planned 
interventions, so that frail persons receive best supportive care 
only, whereas patients designated as vulnerable are treated with 
anticancer modalities. However, in the latter category, doses are 
often reduced, drugs substituted, and regimens switched in order 
to prevent excessive toxicity (53).
TReATMeNT OF PRiMARY NON-
MeTASTATiC HeAD AND NeCK CANCeR
At present, all recommendations for management of elderly 
patients diagnosed with SCCHN are based on retrospective 
studies or subset analyses of prospective trials. In primary non-
metastatic tumors, surgery and radiotherapy have remained 
the cornerstones of care. This holds especially for early disease 
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stages, where single-modalities are generally employed with rela-
tively low risk of complications. The current section provides an 
overview of seminal publications on available treatment modali-
ties to show to what extent a standard approach can be adopted 
in elderly patients. Readers further interested in treatment 
algorithms for SCCHN are advised to refer to clinical practice 
guidelines of the NCCN or the European Society for Medical 
Oncology (ESMO) (54, 55).
In oncology, when comparing the efficacy of different inter-
ventions within a controlled trial, classical endpoints include 
overall or event-free survival. Although regarded as a gold 
standard to demonstrate a clinically meaningful benefit, their 
downside is the fact that they combine one or more disease-
specific events with death from other causes. In the elderly, 
the risk of competing mortality is even higher, necessitating 
the development of accurate prognostic models for stratifying 
patients according to their probability of dying of cancer- versus 
non-cancer-related causes. Recently, a novel generalized com-
peting event model showed an improved stratification of older 
cancer patients compared to standard Cox modeling approaches. 
The authors calculated risk scores for cancer-specific and all-
cause mortalities in 84,319 senior patients (age over 66 years) 
with non-metastatic prostate, head and neck, and breast cancers 
identified from the SEER database. In the head and neck cancer 
subgroup (n = 9,677) diagnosed from 1996 to 2009, the 5-year 
cumulative incidences of all-cause, cancer-specific, second 
cancer, and non-cancer mortality were 59, 24, 16, and 19%, 
respectively. Interestingly, the new model gave more weight to 
female gender, suggesting a possible benefit of treatment inten-
sification for elderly women with SCCHN. The authors conclude 
that this improved risk stratification will help detect treatment 
benefits within subpopulations, leading to more powerful and 
cost-effective clinical research (56).
Surgery
One of the first reports on the risks of major head and neck 
surgery dates back to the late 1970s, when McGuirt and cow-
orkers reviewed medical records of 714 cases who underwent 
radical neck dissection from 1963 to 1973. One hundred sixty-
two patients were over 70 years old. Major surgical complica-
tions included operative mortality, cutaneous fistula, carotid 
blowout, or hemorrhage, while minor complications were 
defined as wound infections, necrosis, seroma, chylous fistula, 
or flap elevation from hematoma formation. The incidence of 
both major and minor surgical complications was comparable 
between the cohorts above and below 70 years of age. However, 
medical complications, mostly of cardiovascular and pulmonary 
origin, were higher by 8% in the elderly subgroup. Perioperative 
mortality rates, defined as death within 30  days of operation, 
were 7.4 and 1.4% in older and younger subjects, respectively 
(57). The perioperative mortality was also addressed in a large 
retrospective study of 810 patients aged over 65 years, where the 
rate was calculated at 3.5% (58). Smaller series later published 
by other investigators showed similar findings even in the 
oldest-old category. As an example, Clayman et  al. compared 
79 patients younger than 65 years with 43 aged over 80 years. 
Although median overall survival was significantly lower in the 
older age group, it was similar to the actuarial survival of the 
general octogenarian population. Moreover, despite a higher 
rate of preoperative comorbid conditions in the older age group, 
the investigators did not observe significant differences in terms 
of perioperative or postoperative complications between the two 
study arms (59).
Although preferred, conservative, non-destructive surgical 
procedures are not always feasible. Therefore, reconstructive sur-
gery with microvascular free tissue transfer has become an inte-
gral part of aggressive surgical interventions. It can be used safely 
and effectively in the elderly population. The reported higher 
rate of perioperative complications with this approach was most 
likely more a result of an increased prevalence of comorbid condi-
tions rather than advanced chronological age (18). In SCCHN, 
comorbidities have indeed been identified as the main predictive 
factor for postoperative complications. A study by Ferrier et al. 
linked duration of anesthesia and comorbidity, measured by the 
ACE-27 or the American Society of Anesthesiologists (ASA) risk 
classification system, to the incidence of major complications of 
head and neck surgery (60). These results were confirmed and 
further extended by Sanabria et al., who retrospectively analyzed 
272 patients older than 70 years. The majority of these patients 
had locally advanced disease. Eighty-eight percent presented with 
comorbidities, and 57% experienced some type of complication 
(45% local and 29% systemic). The following factors were associ-
ated with an increased rate of postoperative complications: male 
gender, bilateral neck dissection, two or more comorbidities, 
reconstructive surgery, and stage IV SCCHN (61).
Taken together, it has become clear that advanced age itself 
should not be a determinant of eligibility for limited or exten-
sive surgical treatment under the condition of careful preop-
erative evaluation of comorbidities and appropriate perioperative 
management.
Radiotherapy
External beam radiotherapy can be delivered either as a defini-
tive treatment with both curative and palliative indications or 
adjuvantly. Combinations with certain anticancer agents (e.g., 
cisplatin or cetuximab) might lead to improved outcome when 
used for the right indication, however, at the cost of increased 
acute and late toxicity. In early disease, radiotherapy yields 
outcomes comparable with resection, and it may become the 
preferred option if a patient is deemed unsuitable for surgery 
or when there is a high risk of a major functional deficit after 
invasive intervention.
The key question whether age represents a deciding factor 
for irradiation was placed in the spotlight of researchers already 
two decades ago, when Pignon and coworkers published an 
article aptly entitled “No age limit for radical radiotherapy in 
head and neck tumours.” This pivotal meta-analysis pooled data 
from 1,589 patients (26% over 65 years) enrolled in five EORTC 
trials. Survival and toxicity were examined after splitting the 
database in seven age categories, three of which belonged to the 
elderly population (65–69, 70–75, >75). No differences were 
observed in overall survival, locoregional control, acute objec-
tive mucosal reactions, weight loss, and late effects. However, 
functional mucosal reactions, corresponding to symptoms 
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experienced by the patients, were more common in older adults. 
Although this age dependency disappeared after adjustment for 
performance status, it suggested that elderly people might toler-
ate acute toxicity less well than their younger counterparts (62). 
Results from other retrospective studies, which were also acces-
sible for the oldest generation (over 85 years), confirmed that 
chronological age is not a relevant discriminator in this setting 
(18). However, these findings should not be interpreted as if all 
patients received full treatment. In a cohort of 331 patients aged 
over 70 years, consistency with institutional policies was as low 
as about 50% (63). Moreover, Ortholan et al. reported a planned 
deviation from standard curative treatment, comprising mostly 
definitive or adjuvant radiotherapy, in 59% of patients aged 
80 years or older (64).
Another matter of importance concerns fractionation sched-
ules. According to a large meta-analysis of 15 trials enrolling 
6,515 SCCHN patients, altered radiotherapy improved locore-
gional control and survival with the greatest benefit conferred by 
hyperfractionation. However, the beneficial effect of altered frac-
tionation decreased with advancing age and poor performance 
status, which was attributed partly to an increased proportion of 
non-cancer-related deaths in the elderly (65). Thus, conventional 
fractionation (1.8–2  Gy per fraction for 5–7  weeks) remains 
the standard-of-care for these patients. On the other hand, less 
intensive schedules can fulfill a role of an effective strategy to 
relief symptoms, when cure is no longer possible. Palliative regi-
mens provide high rates of locoregional responses with a good 
compliance and do not prevent delivery of additional fractions of 
radiotherapy if tolerable (18). Several hypofractionated irradia-
tion schedules were proposed for age-unrestricted populations 
where median age fell within the elderly group, such as 14 Gy in 
4 fractions (range: 52–88, median: 73 years), 30 Gy in 5 fractions 
(range: 43–87, median: 68 years), 50 Gy in 16 fractions (range: 
41–95, median 69  years), 24  Gy in 3 fractions (range: 45–98, 
median: 77 years), or 48 Gy in 12 fractions (range: 39–92, median 
70 years) (66–70). Based on a retrospective study of 65 elderly or 
otherwise frail patients, split-course, accelerated, hypofraction-
ated radiotherapy (SCAHRT) consisting of 60–72 Gy in 20–24 
fractions was recently suggested for properly selected, high-risk 
patients unable to tolerate continuous-course definitive radio-
therapy (71). In addition, stereotactic body radiotherapy may 
represent a promising alternative to purely palliative regimens in 
this patient population (72, 73).
Finally, continuous efforts should be made toward sufficient 
implementation of supportive care measures, not only in the 
palliative setting but throughout the whole treatment period. 
Oral mucositis, pain syndrome, and nutritional deficiency are 
among the most common problems to be timely addressed. In 
this respect, refinements in radiotherapy techniques, compris-
ing, e.g., intensity-modulated radiation therapy (IMRT), offer an 
opportunity to reduce acute and late side effects and should be, 
therefore, promoted (18).
Chemotherapy
In the primary disease setting, chemotherapy has been approved 
for the management of locoregional SCCHN as part of induction 
treatment or as an adjunct to radiotherapy. While the former 
option is not unequivocally accepted among professionals, 
concurrent chemoradiotherapy represents a well-established 
modality. A large individual patient-based meta-analysis showed 
that the magnitude of the survival advantage conveyed by con-
comitant chemoradiotherapy is smaller in older (above 70 years) 
than younger adults, probably due to excess of other causes of 
death in this age group (15% in those under 50  years, 39% in 
those over 70 years). Alternatively, elderly patients could have an 
increase in non-cancer-related deaths inflicted by chemotherapy 
(74). The latter explanation is in line with the results of a subset 
analysis of three Radiation Therapy Oncology Group (RTOG) 
trials (RTOG 91-11, 97-03, and 99-14), which found that older 
age is an independent risk factor for the development of severe 
late toxicity after concurrent chemoradiotherapy (odds ratio 1.05 
per year; p = 0.001) (75).
The effect of age on outcome was also evaluated in a retro-
spective analysis of three other phase III RTOG trials (RTOG 
9003, 0129, and 0522), exploring radiotherapy with or without 
concurrent chemotherapy in the locally advanced setting. Here, 
patients at the age of 70  years or above were more likely to 
be female and to have a poorer performance status, a heavier 
smoking history, and a negative p16 status (p < 0.001 for each). 
Importantly, after adjusting for covariates, they had worse out-
come [hazard ratio (HR) for death: 1.55; 95% confidence interval 
(CI), 1.35–1.77; p < 0.001], regardless of smoking history or p16 
status, and this was more apparent in the combined modality 
trials (RTOG 0129 and 0522), which also featured elevated 
toxicity (see below). Moreover, the adverse effect of older age 
was suggested to be worse in p16 positive cases (HR 2.07 versus 
1.30; interaction p = 0.09). In the RTOG 9003 trial comparing 
two types of radiotherapy (standard versus altered fractionation 
radiotherapy), maximum grade stomatitis and other toxicities 
were similar by age. However, in the two cisplatin-based con-
current chemoradiation studies (RTOG 0129 and 0522), the 
elderly patients experienced significantly more grade 3–5 
thrombocytopenia (p = 0.02), anemia (p = 0.03), nephrotoxicity 
(p = 0.01), and ototoxicity (borderline significant; p = 0.06) than 
the younger patients, whereas surprisingly, severe mucositis 
occurred significantly less frequently in the elderly patients 
(p = 0.04). With regard to causes of death by age, there was no 
difference in incident cancers or second primary tumors, signal-
ing that the shorter survival in older adults was due to other 
causes (34.8 versus 19.5% in younger counterparts) (76).
So, does this mean that elderly patients should not be treated 
with concurrent chemoradiotherapy, which may even decrease 
survival and elicit significantly more acute and late toxicity? 
Adding further to the controversy, two large studies of popula-
tion-based cross-sectional registries provided an alternative view 
on this matter. Retrospective data obtained from the University 
of North Carolina Cancer Registry indicate that elderly SCCHN 
patients (≥ 70 years), fit enough to receive multimodality therapy 
(either surgery plus radiation or chemotherapy plus radiotherapy 
with or without surgery) for stage III–IV disease, have 5-year sur-
vival rates comparable to similarly treated younger counterparts 
(33 versus 44%, p = 0.0522), but do significantly worse if treated 
with single-modality treatment (HR for progression-free survival, 
1.5; 95% CI, 1.19–1.89). More specifically, no negative impact of 
TABLe 4 | is concurrenta chemoradiation a viable option for elderly patients?
Reference Data source inclusion period Definition of  
elderly (years)
Proportion of  
elderly patients
is chemoRT recommended?
Answer explanation
Pignon et al. (74) Controlled trials 1965–2000 >70 8% (out of 14,493) No No survival benefit over RT alone
Machtay et al. (75) Controlled trials 1992–2000 >70 12% (27/230) No Increase in late toxicityb
Kish et al. (76) Controlled trials 1991–1997 and 
2002–2009
≥70 11% (309/2,688) No Worse survivalc and more common acute 
grade 3–5 toxicityb
Moye et al. (24) Cancer registry 1990–2005 ≥70 19% (281/1,447) Yes Similar progression-free and overall survivalb
Amini et al. (77) Cancer registry 1998–2011 >70 100% (4,042) Yes Survival benefit over RT alone in selected 
patients
VanderWalde  
et al. (78)
Cancer registry 1992–2007 >65 100% (10,599) No No survival benefit over RT alone
aChemotherapy scheduling was not specified in the studies by Moye et al. and VanderWalde et al.; RT, radiotherapy.
bCompared with younger counterparts.
cBut no difference in incident cancers or second primary tumors.
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advanced age on overall survival (HR, 1.08; 95% CI, 0.83–1.40) or 
progression-free survival (HR, 1.05; 95% CI, 0.82–1.34) was seen 
for chemotherapy combined with radiotherapy on multivariate 
analysis, although information about chemotherapy scheduling 
was lacking. In addition, early-stage patients from both age groups 
relapsed at the same rate, suggesting that the observed survival 
differences between them were mainly due to non-cancer-
competing mortality (24). A recent review of 4,042 patients older 
than 70 years from the National Cancer Data Base confirmed an 
overall survival benefit of adding chemotherapy concurrently 
to irradiation. This was demonstrated in multivariate analysis 
(HR, 0.63; 95% CI, 0.58–0.68; p < 0.001) and propensity score 
matching (HR, 0.73; 95% CI, 0.66–0.80; p < 0.001). According 
to recursive partitioning analysis, the survival gain was limited 
to patients not older than 81 years, with low comorbidity scores, 
and either T1-2/N2-3 or T3-4/N0-3 disease (77).
However, using the SEER-Medline linked database, 
VanderWalde et al. came to different conclusions. For the entire 
cohort of 10,599 non-metastatic SCCHN patients with a median 
age of 74 years, the unadjusted multivariate Cox regression model 
demonstrated no survival benefit for chemoradiotherapy over 
radiotherapy alone (HR, 1.134; 95% CI, 1.017–1.203; p < 0.001). 
Furthermore, the multivariate analysis identified the following 
characteristics to be significantly associated with overall survival: 
comorbidities, Medicare eligibility, stage, lymph node status, 
IMRT receipt, marital status, cancer site, grade, diagnostic era, 
and age. Of note, the authors did not categorize induction and 
concurrent chemotherapy schedules separately (78).
Altogether, these results illustrate how difficult it is to make 
firm recommendations based on retrospective findings and sub-
group analyses which typically suffer from underrepresentation 
of the elderly population (Table 4). For a correct interpretation, it 
is necessary to distinguish between studies comparing concurrent 
chemoradiation in older patients with concurrent chemoradiation 
in their younger counterparts and studies comparing concurrent 
chemoradiation with radiation only in the elderly population. 
Moreover, we have to take into account that the inclusion period 
of some studies started more than 20 years ago and older people 
nowadays (Boomers) are different from their parents’ generation 
(see above). Another important factor deserving consideration is 
the differentiation between findings coming from a meta-analysis 
of controlled clinical trials on one side and a population-based 
registry on the other. Both approaches have specific limitations 
concerning an often questionable generalizability of results 
in the former category and the purely observational nature of 
acquired data in the latter category. Although the well-known 
and often cited meta-analysis by Pignon et al. may discourage us 
from opting for concurrent chemoradiotherapy in older persons, 
other investigators are more tolerant proposing this modality to a 
specific group of the elderly defined primarily by low comorbidity 
scores. Indeed, the impact of comorbidities and non-adherence 
to treatment protocols on worse outcomes warrants further 
investigation, preferably within a framework of a well-designed 
prospective trial.
In any case, attentive supportive care is imperative in these 
patients (79, 80). As a result of age-related changes in pharmacoki-
netics and pharmacodynamics, chemotherapy administration 
carries safety concerns in the elderly. The physiological decline 
in glomerular filtration rate, caused by reduced renal blood flow, 
necessitates dose adjustments or even omission of some chemo-
therapeutics (e.g., cisplatin, carboplatin, methotrexate). In this 
respect, cisplatin may be replaced with carboplatin, which can 
be dosed more easily based on the glomerular filtration rate (81). 
Importantly, serum creatinine level is not a sensitive indicator 
of renal function in the elderly. Effects on the gastrointestinal 
tract involve a decrease in splanchnic blood blow, production of 
hydrochloric acid, and gastric enzymes, interfering with the rate 
of absorption of many oral drugs, but also reduced liver mass 
and activity of the cytochrome P450 enzymes, which should be 
kept in mind when prescribing medication with exclusive liver 
metabolism (e.g., opioids). Another consideration relates to the 
higher incidence of preexisting neuropathy and the resulting 
drug restrictions (cisplatin, vinca alkaloids, taxanes). In addition, 
older adults are more susceptible to dehydration, and this can 
be precipitated by 5-fluorouracil and other fluoropyrimidines 
as these agents are associated with an increased risk of diarrhea 
and mucositis. The potential danger of 5-fluorouracil is further 
accentuated by the fact that the elderly have a physiologic decline 
in intracellular levels of dihydropyrimidine dehydrogenase, the 
rate-limiting enzyme in the catabolism of fluoropyrimidines. 
TABLe 5 | Predictive model for chemotherapy toxicity (83).
items Score
 1. Age of patient 2 = 72 years or older
0 = less than 72 years
 2. Cancer type 2 = gastrointestinal or genitourinary
0 = other
 3. Planned chemotherapy dose 2 = standard
0 = upfront reduction
 4. Planned number of chemotherapy 
drugs
2 = polychemotherapy
0 = monochemotherapy
 5. Hemoglobin 3 = male: <11 g/dL, female: <10 g/dL
0 = male: ≥11 g/dL, female: ≥10 g/dL
 6. Creatinine clearance (Jeliffe, ideal 
weight)
3 = less than 34 mL/min
0 = 34 mL/min or more
 7. How is your hearing (with a hearing 
aid, if needed)?
2 = fair, poor, or totally deaf
0 = excellent or good
 8. Number of falls in the past 6 months 3 = 1 or more
0 = none
 9. Can you take your own medicine? 1 = with some help/unable
0 = without help
10. Does your health limit you in walking 
one block?
2 = somewhat limited/limited a lot
0 = not limited at all
11. During the past 4 weeks, how much 
of the time has your physical health 
or emotional problems interfered 
with your social activities (like visiting 
with friends, relatives, etc.)?
1 = limited at least some of the time
0 = limited a little of the time or not at all
Total score 0–5 points: low risk of toxicity
6–9 points: intermediate risk of  
   toxicity
10–19 points: high risk of toxicity
Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights 
reserved.
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Apart from that, age over 65 years is an important predisposi-
tion for chemotherapy-induced myelosuppression and febrile 
neutropenia. In this setting, hematopoietic growth factor sup-
port has proved beneficial (53). Finally, polypharmacy and the 
resulting drug–drug interactions may become a serious issue. 
Around 40% of elderly patients take more than four different 
drugs, which increases the risk of interactions at least fourfold 
compared with taking less medication. Consequently, 75% of 
patients over 70 years treated with chemotherapy are in danger 
of drug interactions (12).
Addressing the need for a better prediction of chemotherapy 
toxicity in this population, Hurria et  al. developed a practice-
oriented risk stratification schema for grade 3–5 toxicity 
incorporating patient, tumor, and treatment characteristics, lab-
oratory test values, and geriatric assessment variables (Table 5) 
(82). Recently, this prediction tool was externally validated in 
an independent cohort of 250 elderly patients (≥65 years) with 
breast (24%), lung (26%), gastrointestinal (27%), gynecological 
(7%), genitourinary (12%), and other cancers (4%). Risk of 
chemotherapy-induced toxicity was shown to significantly cor-
relate with increasing risk score (37% for a low, 62% medium, 
and 70% high score; p < 0.001), but not with Karnofsky perfor-
mance status (83).
Targeted Therapy
Cetuximab (epidermal growth factor receptor [EGFR] inhibitor) 
is the only targeted agent to significantly improve the median 
overall survival of patients with locoregionally advanced and 
recurrent or metastatic SCCHN (84, 85). In the former category, 
the activity of cetuximab has been supported by a controlled 
phase III trial which randomly assigned 424 patients to receive 
either cetuximab plus radiotherapy or radiotherapy alone. 
However, following its introduction in clinical practice 10 years 
ago, real-world experience has been controversial. Not only 
did some authors report a higher-than-expected toxicity but 
more recent data have raised questions whether its efficacy in 
combination with radiotherapy equals that of cisplatin-based 
concurrent chemoradiotherapy (86–91). In the original 2006 
trial, the elderly population represented 26% of the total number 
of enrolled patients (110/424). Unfortunately, based on a subset 
analysis, the overall survival benefit observed with the addition 
of cetuximab was limited to patients younger than 65  years. 
Nevertheless, the compliance with cetuximab plus radiation is 
clearly superior to that observed with cisplatin-based concur-
rent chemoradiotherapy. Moreover, the addition of cetuximab to 
radiotherapy did not have a negative effect on quality of life (92). 
Therefore, in case there are absolute or relative contraindica-
tions for the use of cisplatin, cetuximab remains a viable option, 
regardless of advanced age (93).
immune Modulation
Modern immunotherapeutic approaches using immune check-
point inhibitors have emerged as a ground-breaking discovery 
in oncology. The principle behind their action is restoration of 
the natural anticancer potential of the immune system. SCCHN 
is an immunosuppressive disease employing several mecha-
nisms to evade immune surveillance. It manipulates its own 
immunogenicity, produces immunosuppressive mediators, and 
promotes immunomodulatory cell types (94). The process of 
aging is accompanied by a gradual decline in immune functions. 
However, the role of this phenomenon, referred to as immunose-
nescence, in cancer development remains a matter of debate. On 
the one hand, immunosurveillance, recognizing and eliminating 
malignant cells, becomes compromised with advancing age; on 
the other hand, the immune system displays tumor-promoting 
properties, which may decrease in the elderly as well. Thus, the 
possible reason for increased cancer incidence with respect to the 
immune system could be the chronic inflammatory responses 
observed in aging tissues (13).
Another crucial observation concerns the fact that both chem-
otherapy (e.g., oxaliplatin, cyclophosphamide) and radiation can 
initiate effective antitumor immunity by inducing immunogenic 
cell death, leading to dendritic cell activation (95–97). Intriguingly, 
radiotherapy has been put in context with the so-called abscopal 
effect also known as radiation-induced bystander effect, a situa-
tion when localized treatment of a tumor mass results in a shrink-
ing of distant lesions. Although the underlying mechanisms have 
not yet been fully understood, various combinations of immune 
checkpoint inhibitors with other anticancer treatment modalities 
have gained attention among the medical community, being 
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supported by favorable preclinical experience (98). Three major 
classes of checkpoint inhibitors are available for clinical testing. 
They encompass monoclonal antibodies against anti-cytotoxic 
T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1) 
receptor, and programmed death ligand-1 (PD-L1). Trials ongo-
ing in previously untreated, locally advanced SCCHN investigate 
a combination of ipilimumab (anti-CTLA-4) with cetuximab-
based bioradiotherapy (NCT01860430), nivolumab (anti-PD-1) 
with cetuximab- or cisplatin-based bio- or chemoradiotherapy 
(RTOG3504), and pembrolizumab (anti-PD-1) with cisplatin-
based concurrent chemoradiotherapy (NCT02819752) (94). 
Currently, it is unclear whether old age has any impact on the 
outcome of such combination regimens. However, recent data 
from immunotherapy trials conducted in R/M-SCCHN indicate 
that senior patients might be able to tolerate checkpoint inhibi-
tors well (see below).
TReATMeNT OF ReCURReNT AND/OR 
MeTASTATiC HeAD AND NeCK CANCeR
R/M-SCCHN is a devastating disease qualifying most of the 
patients for palliative measures with an expected survival usu-
ally not exceeding 1 year. Owing to the higher risk of competing 
causes of death in the older adults and their often compromised 
health status, the prognosis is even worse in this population, 
which partly explains the profound lack of high-level evidence 
to guide clinical management. Generally, eligibility for and toler-
ance to a locoregional approach (surgery and radiation) is better 
than in the case of systemic therapy. However, just a minority 
of locoregional recurrences can be successfully salvaged by com-
plete resection or (re)irradiation (99). Similarly, only carefully 
selected cases with metachronous pulmonary metastases may be 
considered for surgical intervention (100). After reviewing medi-
cal records of 75 consecutive SCCHN patients who underwent 
reirradiation, Buglione et al. identified the following unfavorable 
prognostic factors for overall survival on univariate analysis: age 
above 70, Karnofsky performance status below 90, and more than 
three comorbidities (101).
In the remainder, irrespective of age, treatment goals focus 
primarily on symptom control and improvement of quality of 
life. A single-drug regimen or best supportive care is offered to 
fragile patients with poor performance status and comorbidities. 
Fit individuals may benefit from multi-drug chemotherapy with 
or without cetuximab (99). The landmark EXTREME (Erbitux 
in first-line treatment of recurrent or metastatic head and neck 
cancer) trial found significant overall survival improvement with 
platinum (cisplatin or carboplatin)/5-fluorouracil/cetuximab 
combination over the chemotherapy doublet  alone and, there-
fore, is the only approved standard first-line systemic treatment 
today (85).
In a combined analysis of two phase III trials conducted by 
ECOG (1393 and 1395), Argiris et al. compared toxicity, response 
rates, and survival of elderly R/M-SCCHN patients (70 years or 
older) with their younger counterparts. The ECOG 1393 trial 
randomized patients to receive a cisplatin/paclitaxel doublet at 
two dose levels, while treatment arms in the ECOG 1395 trial 
comprised cisplatin plus either 5-fluorouracil or paclitaxel. 
Altogether, 53 older patients were compared to 346 younger 
ones. No statistically significant differences were observed in 
terms of objective response rate (28 versus 33%), median time 
to progression (5.25 versus 4.8 months), median overall survival 
(5.3 versus 8 months), or 1-year survival (26 versus 33%) between 
these two subgroups, respectively. However, the authors noted 
a significantly higher incidence of severe nephrotoxicity, diar-
rhea, and thrombocytopenia in the elderly population, which 
was accompanied by a trend toward a higher toxic death rate 
(13 versus 8%). In conclusion, cisplatin-based doublets yielded 
comparable survival outcomes among fit elderly and younger 
patients, yet at the cost of increased side effects in the former 
group (20).
Population aged 65 years or more made up 17% of the total 
number of patients (77/442) enrolled in the EXTREME trial and 
was equally distributed between both treatment arms. Subgroup 
analysis of this cohort revealed that the survival advantage 
conferred by adding cetuximab to platinum/5-fluorouracil 
chemotherapy fell short of statistical significance, in contrast 
to younger adults and the whole intention-to-treat population. 
Median progression-free survival was 4.2 and 3.2 months (HR, 
0.65; 95% CI, 0.38–1.12) and median overall survival 9.1 and 
7.8  months (HR, 1.07; 95% CI, 0.65–1.77), in the cetuximab 
and control arms of the elderly subpopulation, respectively (85). 
Analogous data are available in the second-line setting. The 
LUX-Head and Neck 1 trial evaluated the clinical efficacy of 
afatinib, an irreversible human epidermal growth factor family 
receptor (ERBB) blocker, matched up to methotrexate in a 2:1 
ratio among 483 eligible subjects [128 (27%) aged 65  years 
or more]. Although the study was sufficiently powered, no 
improvement in overall survival was achieved by the ERBB 
antagonist. However, afatinib induced a marginal but signifi-
cant improvement in median progression-free survival versus 
methotrexate in the overall population (2.6 versus 1.7 months; 
HR, 0.80; 95% CI, 0.65–0.98, p  =  0.030) (102). Moreover, 
similar progression-free survival benefit with afatinib versus 
methotrexate was observed in patients aged 65  years or older 
(2.8 versus 2.3 months; HR, 0.68; 95% CI, 0.45–1.03, p = 0.061) 
and younger patients (2.6 versus 1.6 months; HR, 0.79; 95% CI, 
0.62–1.01, p = 0.052). Also objective response rates with afatinib 
versus methotrexate were 11 versus 7% and 10 versus 5% and 
disease control rates were 53 versus 38% and 48 versus 39% 
in older and younger patients, respectively, without an indica-
tion of excessive toxicity in the older population (103). Taken 
together, these results suggest that benefit of systemic treatment 
also exists in the elderly, but newer forms of systemic therapy 
need to be studied prospectively and separately in the elderly 
population with R/M-SCCHN.
One of the novel systemic strategies involves immunotherapy, 
particularly immune checkpoint inhibitors. These agents have the 
potential to induce durable responses even in patients with refrac-
tory disease and cause relatively low incidence of serious adverse 
events. In SCCHN, available data from clinical trials have not 
been published in peer-reviewed journals so far. In the recently 
reported interim analysis of the phase III CHECKMATE-141 
trial, nivolumab, as the first drug ever, improved median overall 
survival in platinum-refractory R/M-SCCHN, compared with 
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single-agent chemotherapy or cetuximab. Of the 361 enrolled 
patients, 113 (31%) were 65  years or older. Unfortunately, 
the survival benefit of nivolumab observed in patients aged 
65–74 years did not reach statistical significance (HR, 0.93; 95% 
CI, 0.56–1.54), which was thus limited to their younger coun-
terparts (104). Additional promising results were presented from 
early clinical trials exploring pembrolizumab and durvalumab 
(anti-PD-L1) (105, 106). In both studies, elderly patients were 
included in the study population, and treatment even at very old 
age seems possible. Illustrative for that was the case of a 96-year-
old female patient with an HPV-negative and PD-L1-positive 
tumor who progressed on a previous regimen with cetuximab. 
The patient was then started on durvalumab yielding a partial 
response already 4 weeks after treatment initiation. At 16 weeks 
of durvalumab administration, tumor shrinkage was confirmed. 
Surprisingly, the authors mentioned that no treatment-related 
adverse events occurred (106).
Broadly addressing the issue of SCCHN unsuitable for surgery, 
the ELAN-ONCOVAL study was designed to establish a standard 
treatment for individuals aged 70  years or over. It is currently 
recruiting patients who undergo a geriatric evaluation upon 
enrollment and then enter one of the following three distinct 
trials. In the curative setting, unfit patients are offered radio-
therapy (standard versus hypofractionated split course schedule) 
within the randomized non-inferiority ELAN-RT phase III trial 
(NCT01864850). In the recurrent and/or metastatic setting, unfit 
patients are proposed to be enrolled in the ELAN-UNFIT phase III 
trial (NCT01884623) comparing single-agent cetuximab versus 
methotrexate monotherapy, whereas the fit ones may participate 
in the ELAN-FIT phase II trial (NCT01864772) evaluating the 
carboplatin/5-fluororuracil/cetuximab (EXTREME) regimen. 
The ELAN-ONCOVAL is planned to enroll 448 patients with an 
estimated completion date between 2017 and 2018 (107).
CONCLUSiON
Progress in oncology research and innovative approaches to trial 
design have been paralleled by a process of extending allocation 
of health resources. Oncological care has become more intensive 
and sophisticated, equipped with detailed guidelines covering 
nearly all age groups, stages, and histotypes. Long gone is the time 
when older adults were eligible only for palliative management. 
Senior patients have repeatedly shown enough benefit to out-
weigh the possible complications related to physiological changes 
occurring with advancing age. To achieve cure, accumulating 
evidence suggests that fit elderly people should be treated accord-
ing to protocols used for their younger counterparts but need to 
undergo a more scientifically based selection procedure and in 
addition need the most optimal support to be able to tolerate 
these standard treatments. The time has come to make a change 
and stop ending up each time with insufficient numbers of elderly 
patients in trials with unrestricted age distribution. Taking into 
account the changing demographics in head and neck cancer, 
better options seem recommendable.
Therefore, to better understand the behavior of head and 
neck cancer in elderly patients and to come to a better man-
agement of such patients, we support the idea to develop and 
implement elderly specific prospective trials instead of settling 
for stratification based on age. Moreover, integration of formal 
geriatric assessment with comorbidity scores in treatment plans 
should take into account a direct applicability to the daily clinical 
practice. In trial design, the SIOG advocates an appropriate use 
of de-escalation protocols and endpoints relating to functional 
status, cognition, and independent living (12). Finally, as sug-
gested by Kish et  al., the institution of predictive models for 
chemotherapy toxicity and outcome, examination of tumor 
genetics, and comparative molecular genomic analysis of elderly 
patients versus their younger counterparts may further assist 
us in defining new standard-of-care treatment for this elderly 
population (76).
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